| pubmed-article:17942308 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17942308 | lifeskim:mentions | umls-concept:C0008972 | lld:lifeskim |
| pubmed-article:17942308 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:17942308 | lifeskim:mentions | umls-concept:C0020792 | lld:lifeskim |
| pubmed-article:17942308 | lifeskim:mentions | umls-concept:C1705480 | lld:lifeskim |
| pubmed-article:17942308 | lifeskim:mentions | umls-concept:C1181159 | lld:lifeskim |
| pubmed-article:17942308 | lifeskim:mentions | umls-concept:C0205415 | lld:lifeskim |
| pubmed-article:17942308 | lifeskim:mentions | umls-concept:C0162829 | lld:lifeskim |
| pubmed-article:17942308 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:17942308 | lifeskim:mentions | umls-concept:C2351763 | lld:lifeskim |
| pubmed-article:17942308 | pubmed:issue | 23 | lld:pubmed |
| pubmed-article:17942308 | pubmed:dateCreated | 2007-11-6 | lld:pubmed |
| pubmed-article:17942308 | pubmed:abstractText | We have continued to explore spirobenzazepines as vasopressin receptor antagonists to follow up on RWJ-339489 (2), which had advanced into preclinical development. Further structural modifications were pursued to find a suitable backup compound for human clinical studies. Thus, we identified carboxylic acid derivative 3 (RWJ-676070; JNJ-17158063) as a potent, balanced vasopressin V(1a)/V(2) receptor antagonist with favorable properties for clinical development. Compound 3 is currently undergoing human clinical investigation. | lld:pubmed |
| pubmed-article:17942308 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17942308 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17942308 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17942308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17942308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17942308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17942308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17942308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17942308 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17942308 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:17942308 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:17942308 | pubmed:author | pubmed-author:MaryanoffBruc... | lld:pubmed |
| pubmed-article:17942308 | pubmed:author | pubmed-author:WangYuanpingY | lld:pubmed |
| pubmed-article:17942308 | pubmed:author | pubmed-author:PatelMonaM | lld:pubmed |
| pubmed-article:17942308 | pubmed:author | pubmed-author:DemarestKeith... | lld:pubmed |
| pubmed-article:17942308 | pubmed:author | pubmed-author:GunnetJoseph... | lld:pubmed |
| pubmed-article:17942308 | pubmed:author | pubmed-author:LookRichardR | lld:pubmed |
| pubmed-article:17942308 | pubmed:author | pubmed-author:DamianoBruce... | lld:pubmed |
| pubmed-article:17942308 | pubmed:author | pubmed-author:ZhangHan-Chen... | lld:pubmed |
| pubmed-article:17942308 | pubmed:author | pubmed-author:RybczynskiPhi... | lld:pubmed |
| pubmed-article:17942308 | pubmed:author | pubmed-author:McComseyDavid... | lld:pubmed |
| pubmed-article:17942308 | pubmed:author | pubmed-author:MinorLisa KLK | lld:pubmed |
| pubmed-article:17942308 | pubmed:author | pubmed-author:ChenRobert... | lld:pubmed |
| pubmed-article:17942308 | pubmed:author | pubmed-author:XiangMin... | lld:pubmed |
| pubmed-article:17942308 | pubmed:author | pubmed-author:ZhongH... | lld:pubmed |
| pubmed-article:17942308 | pubmed:author | pubmed-author:VillaniFrank... | lld:pubmed |
| pubmed-article:17942308 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17942308 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:17942308 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:17942308 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17942308 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17942308 | pubmed:pagination | 6623-8 | lld:pubmed |
| pubmed-article:17942308 | pubmed:meshHeading | pubmed-meshheading:17942308... | lld:pubmed |
| pubmed-article:17942308 | pubmed:meshHeading | pubmed-meshheading:17942308... | lld:pubmed |
| pubmed-article:17942308 | pubmed:meshHeading | pubmed-meshheading:17942308... | lld:pubmed |
| pubmed-article:17942308 | pubmed:meshHeading | pubmed-meshheading:17942308... | lld:pubmed |
| pubmed-article:17942308 | pubmed:meshHeading | pubmed-meshheading:17942308... | lld:pubmed |
| pubmed-article:17942308 | pubmed:meshHeading | pubmed-meshheading:17942308... | lld:pubmed |
| pubmed-article:17942308 | pubmed:meshHeading | pubmed-meshheading:17942308... | lld:pubmed |
| pubmed-article:17942308 | pubmed:meshHeading | pubmed-meshheading:17942308... | lld:pubmed |
| pubmed-article:17942308 | pubmed:meshHeading | pubmed-meshheading:17942308... | lld:pubmed |
| pubmed-article:17942308 | pubmed:meshHeading | pubmed-meshheading:17942308... | lld:pubmed |
| pubmed-article:17942308 | pubmed:meshHeading | pubmed-meshheading:17942308... | lld:pubmed |
| pubmed-article:17942308 | pubmed:meshHeading | pubmed-meshheading:17942308... | lld:pubmed |
| pubmed-article:17942308 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17942308 | pubmed:articleTitle | Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies. | lld:pubmed |
| pubmed-article:17942308 | pubmed:affiliation | Research and Early Development, Johnson & Johnson Pharmaceutical Research & Development, 8 Clarke Drive, Cranbury, NJ 08512, USA. | lld:pubmed |
| pubmed-article:17942308 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17942308 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:17942308 | lld:chembl |
